Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBPNASDAQ:GNTANASDAQ:IGMSNASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.28-7.0%$0.00$0.22▼$15.80$14.09M0.914.12 million shs3.50 million shsGNTAGenenta Science$3.10+1.6%$3.99$2.79▼$7.28$56.70M0.7315,276 shs17,883 shsIGMSIGM Biosciences$1.08-11.5%$1.24$0.92▼$22.50$64.56M0.52310,422 shs2.43 million shsIMRXImmuneering$3.53+10.7%$1.79$1.00▼$3.87$127.03M0.012.55 million shs2.75 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-1.90%+28,449,900.00%+28,449,900.00%+28,449,900.00%GNTAGenenta Science0.00%+0.85%-27.42%-22.01%-7.19%IGMSIGM Biosciences0.00%-7.69%-18.80%-12.90%-83.86%IMRXImmuneering0.00%+37.89%+108.26%+115.24%+155.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AGNTAGenenta Science2.596 of 5 stars3.53.00.00.03.31.70.0IGMSIGM Biosciences4.4248 of 5 stars3.04.00.04.62.33.30.6IMRXImmuneering4.0185 of 5 stars3.34.00.00.04.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/AGNTAGenenta Science 3.00Buy$25.00706.45% UpsideIGMSIGM Biosciences 1.90Reduce$5.50409.26% UpsideIMRXImmuneering 2.60Moderate Buy$13.25275.35% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, IGMS, GNTA, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIGMSIGM Biosciences$2.68M24.09N/AN/A$0.82 per share1.32IMRXImmuneering$320K397.01N/AN/A$1.33 per share2.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/AGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIGMSIGM Biosciences-$195.79M-$3.27N/AN/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)IMRXImmuneering-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)Latest ASBP, IGMS, GNTA, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.220.22GNTAGenenta ScienceN/A6.896.89IGMSIGM BiosciencesN/A5.715.71IMRXImmuneeringN/A7.487.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%GNTAGenenta Science15.13%IGMSIGM Biosciences42.79%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%GNTAGenenta Science28.99%IGMSIGM Biosciences57.00%IMRXImmuneering22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/AGNTAGenenta Science718.29 million12.99 millionNot OptionableIGMSIGM Biosciences19059.78 million25.70 millionOptionableIMRXImmuneering6035.99 million27.75 millionNot OptionableASBP, IGMS, GNTA, and IMRX HeadlinesRecent News About These CompaniesAnalysts Set Immuneering Corporation (NASDAQ:IMRX) PT at $13.25June 26 at 3:35 AM | americanbankingnews.comImmuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 6,007 SharesJune 25, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Purchases 6,007 SharesJune 24, 2025 | marketbeat.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) Insider Buys 7,415 Shares of StockJune 24, 2025 | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg Buys 25,000 SharesJune 23, 2025 | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 SharesJune 21, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 21, 2025 | marketbeat.comWe're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn RateJune 20, 2025 | finance.yahoo.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) CEO Purchases 21,000 Shares of StockJune 20, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given "Buy" Rating at Needham & Company LLCJune 20, 2025 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Price Target Raised to $10.00 at MizuhoJune 20, 2025 | americanbankingnews.comPre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIOJune 19, 2025 | nasdaq.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Acquires 40,485 Shares of StockJune 19, 2025 | insidertrades.comChardan Capital Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)June 19, 2025 | americanbankingnews.comPositive Phase IIa OS data on Immuneering’s novel MEK inhibitorJune 18, 2025 | thepharmaletter.comTImmuneering Corporation (NASDAQ:IMRX) Director Acquires $89,471.85 in StockJune 18, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Price Target Raised to $10.00June 18, 2025 | marketbeat.comChardan Capital Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)June 18, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLCJune 18, 2025 | marketbeat.comImmuneering Corporation to Host Conference Call for Phase 2a Clinical Trial Update on IMM-1-104 in Pancreatic CancerJune 18, 2025 | nasdaq.comImmuneering stock rises after positive pancreatic cancer trial dataJune 17, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, IGMS, GNTA, and IMRX Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.28 -0.02 (-7.03%) As of 06/27/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Genenta Science NASDAQ:GNTA$3.08 +0.03 (+0.82%) As of 06/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.IGM Biosciences NASDAQ:IGMS$1.08 -0.14 (-11.48%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.18 +0.11 (+9.72%) As of 06/27/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Immuneering NASDAQ:IMRX$3.53 +0.34 (+10.66%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.52 -0.01 (-0.42%) As of 06/27/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
